Mechanistically, coinhibition of both NF-κB and c-JUN contributes to enhancing not only antiproliferation but also antimetastasis and anti-angiogenesis in vivo, which may help to explain the better prognosis in HCC patients. The gene discussed is JUN; the disease is hepatocellular carcinoma.